Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2005-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.COPH.2005.04.007PMID 15955734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

  2005cited by this paper
• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Signaling Specificity by Ras Family GTPases Is Determined by the Full Spectrum of Effectors They Regulate

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• Raf pathway inhibitors in oncology.

  2003cited by this paper
• ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Dominant negative mutants of mitogen-activated protein kinase pathway.

  2001cited by this paper
• Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors.

  2001cited by this paper
• Regulation of Ras·GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-coupled Receptor Agonists and Phorbol Ester

  1999cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• The GTPase superfamily: conserved structure and molecular mechanism

  1991cited by this paper
• The GTPase superfamily: a conserved switch for diverse cell functions

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper
• The ras gene family and human carcinogenesis.

  1988cited by this paper

• Experimentally calibrated multiscale model predicts schedule dependent drug combination effects.

  2026cites this paper
• Pyrazolopyrimidines: A Promising Frontier in Cancer Treatment‐Reviewing Their Potential as Inhibitors of Serine/Threonine Kinases

  2025cites this paper
• Recent Trends in anti-tumor mechanisms and molecular targets of celastrol

  2024cites this paper
• Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase

  2024cites this paper
• Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?

  2024cites this paper
• Inhibition of p38MAPK signalling pathway alleviates radiation‐induced testicular damage through improving spermatogenesis

  2023cites this paper
• A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors

  2023cites this paper
• c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer

  2022cites this paper
• Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma.

  2022cites this paper
• Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

  2022cites this paper
• Knockdown of TTC9 inhibits the proliferation, migration and invasion, but induces the apoptosis of lung adenocarcinoma cells

  2022cites this paper
• Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy

  2022cites this paper
• Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer

  2022cites this paper
• Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance.

  2021cites this paper
• Tomatidine Suppresses the Destructive Behaviors of Fibroblast-Like Synoviocytes and Ameliorates Type II Collagen-Induced Arthritis in Rats

  2021cites this paper
• Nitidine chloride inhibits the appearance of cancer stem-like properties and regulates potential the mitochondrial membrane alterations of colon cancer cells

  2020cites this paper
• Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma

  2020influential citation
• (Curcumin+sildenafil) enhances the efficacy of 5FU and anti‐PD1 therapies in vivo

  2020cites this paper
• Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.

  2020cites this paper
• Targeting Pathways in GI Malignancies

  2020cites this paper
• Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

  2020cites this paper
• Apelin and apelin receptor in human placenta: Expression, signalling pathway and regulation of trophoblast JEG-3 and BeWo cells proliferation and cell cycle

  2020cites this paper
• Modulation of Multiple Signaling Pathways of the Plant-Derived Natural Products in Cancer

  2019cites this paper
• ZHX2 inhibits proliferation and promotes apoptosis of human lung cancer cells through targeting p38MAPK pathway

  2019cites this paper
• R-Spondin3 promotes the tumor growth of choriocarcinoma JEG-3 cells.

  2019cites this paper
• Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer

  2019cites this paper
• How oncogenic mutations activate human MAP kinase 1 (MEK1): a molecular dynamics simulation study

  2019cites this paper
• Kinase suppressor of Ras 1 and Exo70 promote fatty acid-stimulated neurotensin secretion through ERK1/2 signaling

  2019cites this paper
• Automated Text Mining and Ranked List Algorithms for Drug Discovery in Acute Myeloid Leukemia

  2019cites this paper
• Small Molecules in Oncology

  2018cites this paper
• Inhibitory effects of tubeimoside I on synoviocytes and collagen‐induced arthritis in rats

  2018cites this paper
• Oxovanadium phenanthroimidazole derivatives: synthesis, DNA binding and antitumor activities

  2018cites this paper
• Trametinib (GSK1120212).

  2018cites this paper
• Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor

  2018influential citation
• Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains.

  2018cites this paper
• Current Development Status of MEK Inhibitors

  2017cites this paper
• Explorer Characterisation and germline transmission of cultured avian primordial germ cells

  2017influential citation
• A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

  2017cites this paper
• MEK inhibitors in oncology: a patent review (2015-Present)

  2017cites this paper
• Curcumin shifts RAS ‐ induced pro ‐ proliferative MEK/ERK ‐ signaling toward pro ‐ apoptotic p38MAPK/JNK1 ‐ signaling, triggering p53 activation and apoptosis

  2017cites this paper
• MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors

  2017cites this paper
• Role of key genetic mutations on increasing migration of brain cancer cells through confinement

  2017cites this paper
• RAF-MEK-MAPK Pathway Targeted by Tumor Suppression and Anticancer Therapeutic Agents

  2017cites this paper
• Xanthohumol inhibits the extracellular signal regulated kinase (ERK) signalling pathway and suppresses cell growth of lung adenocarcinoma cells.

  2016cites this paper
• Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?

  2016cites this paper
• Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit

  2016cites this paper
• Nitidine chloride inhibits proliferation and induces apoptosis in colorectal cancer cells by suppressing the ERK signaling pathway

  2016cites this paper
• Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways.

  2016cites this paper
• Luteolin Inhibits Proliferation and Induces Apoptosis of Human Placental Choriocarcinoma Cells by Blocking the PI3K/AKT Pathway and Regulating Sterol Regulatory Element Binding Protein Activity1

  2016cites this paper
• Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations

  2016cites this paper
• Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway.

  2016cites this paper
• The synthesis, characterisation and bioapplications of Novel Gold-Zinc Telluride Core-shell Nanoparticles

  2016cites this paper
• CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer

  2016cites this paper
• Targeting irradiation‐induced mitogen‐activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer

  2016cites this paper
• PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.

  2016cites this paper
• Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

  2016cites this paper
• Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines

  2016cites this paper
• Paris saponin VII suppresses osteosarcoma cell migration and invasion by inhibiting MMP-2/9 production via the p38 MAPK signaling pathway

  2016cites this paper
• Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis

  2015cites this paper
• Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma.

  2015cites this paper
• A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

  2015cites this paper
• New hope on the horizon for patients with metastatic colorectal cancer

  2015cites this paper
• Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.

  2015cites this paper
• Selective modulation of MAPKs contribute to the anti-proliferative and anti-inflammatory activities of 1,7-dihydroxy-3,4-dimethoxyxanthone in rheumatoid arthritis-derived fibroblast-like synoviocyte MH7A cells.

  2015cites this paper
• Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.

  2015cites this paper
• PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.

  2015cites this paper
• Overexpression of DDX43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

  2014influential citation
• Nitidine chloride induces apoptosis and inhibits tumor cell proliferation via suppressing ERK signaling pathway in renal cancer.

  2014cites this paper
• Cancer Biology and Signal Transduction Overexpression of DDX 43 Mediates MEK Inhibitor Resistance through RAS Upregulation in Uveal Melanoma Cells

  2014cites this paper
• Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma

  2014cites this paper
• Trametinib.

  2014cites this paper
• The role of MEK inhibitors in the treatment of metastatic melanoma

  2014cites this paper
• Cell fate specification and polarisation in mouse preimplantation epithelia

  2014cites this paper
• Signal Transduction Pathways in Critical Illness and Injury

  2014cites this paper
• Erk/MAP Kinase Signaling Pathway and Neuroendocrine Differentiation of Non–Small-Cell Lung Cancer

  2014cites this paper
• Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.

  2014cites this paper
• Sustained Induction of Collagen Synthesis by TGF-β Requires Regulated Intramembrane Proteolysis of CREB3L1

  2014influential citation
• Insufficient Sleep in Adolescents and Young Adults: An Update on Causes and Consequences

  2014cites this paper
• Studies on mitogen-activated protein kinase signaling pathway in the alveolar macrophages of chronic bronchitis rats

  2014cites this paper
• Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.

  2014cites this paper
• Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity

  2014cites this paper
• Growth Suppression of Colorectal Cancer by Plant-Derived Multiple mAb CO17-1A × BR55 via Inhibition of ERK1/2 Phosphorylation

  2014cites this paper
• Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer

  2014cites this paper
• Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway

  2014cites this paper
• A Polymeric Prodrug of 5-Fluorouracil-1-Acetic Acid Using a Multi-Hydroxyl Polyethylene Glycol Derivative as the Drug Carrier

  2014cites this paper
• Emerging targeted therapies for melanoma treatment (Review)

  2014cites this paper
• Effects of interleukin-22 on epithelial cell transformation and breast tumorigenesis

  2014cites this paper
• Oncogenic ERBB3 mutations in human cancers.

  2013cites this paper
• Simultaneous Inhibition of the Raf/MEK/ERK and PI3K/Atk/mTOR Pathways has Significant Synergistic Effects on Proliferation and Migration in C6 Glioma Cancer Cells

  2013cites this paper
• MEK and the inhibitors: from bench to bedside

  2013cites this paper
• Decoupling Polarization of the Golgi Apparatus and GM1 in the Plasma Membrane

  2013cites this paper
• The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway

  2013cites this paper
• Identification of Genes and Pathways Involved in Schwann Cell Tumor Initiation, Development and Progression to Develop Novel Drug Targets

  2013cites this paper
• YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models

  2013cites this paper
• Abl/Src inhibitor BMS-354/825 MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual

  2013cites this paper
• GRM1, A POTENTIAL TARGET FOR HUMAN MELANOMA

  2013cites this paper
• The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation

  2013cites this paper
• Targeting the PI3K and Ras Signal Transduction Pathways in a Murine Model of Osteolytic Breast Cancer Metastasis

  2013cites this paper
• Discovery and optimisation of small-molecule ERK5 inhibitors as cancer therapeutics

  2013cites this paper
• Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells

  2013cites this paper